The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

According to French scientists, no organ system appears as vulnerable to aging as the cardiovascular system, and anti-aging therapeutics may help mitigate the effects of cardiovascular disease.

(The principal investigator behind the review, aging researcher Guido Kroemer | Olympiad in Cardiovascular Medicine)

Anti-aging therapeutics may prevent and slow age-related cardiovascular dysfunction.

Cardiovascular

In remembrance of Jane Goodall: The science-backed lifestyle factors that likely contributed to her long life and sound mind.  

Jane Goodall, PhD (image: thenationalnews.com).

Aging &amp; Longevity

Model: UM-HET3 Mice 
Dosage: 0, 75, 150, 300, 600, and 1200 ng epicatechin/mg food; 0, 0.075, 0.15, 0.3, 0.6, and 1.2 ng halofuginone/mg food; and 0, 37.5, 75, 150, 300, and 600 ng mitoglitazone/mg food, all given ad libitum in food starting at seven months old

Three Compounds Show Promise for Male Longevity

Data from a rigorous longevity study show promise for three new compounds, adding to the repertoire of mouse lifespan-extending substances.

(The three compounds’ effects on median lifespan extension | Rapamycin Longevity News)

The world’s most rigorous longevity study presents data showing promise for three new lifespan-extending compounds in male mice.

Participants: Healthy older adults 
Dosage: 1 mg/day of rapamycin for 8 weeks

Older adults taking low-dose rapamycin exhibit a reduction in senescent cells — cells that contribute to age-related diseases and a shorter lifespan. 

Associate professor at Oxford University and corresponding author on the study, Lynne S Cox, MA, PhD (image: researchgate.com).

Immunity

Model: C3B6F1 hybrid mice 
Dosage: 42 mg/kg of rapamycin and 1.44 mg/kg of trametinib in food starting at 6 months of age

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29% in female mice and 27% in male mice, respectively.

(The study’s lead author, Linda Partridge | The Biologist)

Combining two cancer treatment drugs, trametinib and rapamycin, extends lifespan by 29% and 27% in middle-aged female and male mice, respectively.

Search Result: aging delay

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

Remembering Jane Goodall: The Simple Habits That Kept Her Mind Sharp for 91 Years

Three Compounds Show Promise for Male Longevity

New Oxford Study: Powerful Longevity Drug Rapamycin Targets Cell Senescence

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan